1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Ionis Buys Out Akcea As Cardiovascular Pipeline Blooms

 
• By Jessica Merrill

The RNA-drug developer, which is buying the approximately 24% of Akcea it doesn't already own for around $500m, highlighted the maturing pipeline in a cardiovascular overview.

Modern Neon Red Glowing Heart Banner on Dark Empty Grunge Brick Background. Vector Vintage Red Heart Sign. Retro Neon Valentines Day Symbol
Ionis is taking back full ownership of its heart-disease focused subsidiary • Source: Shutterstock

Ionis Pharmaceuticals, Inc. is fully buying out its cardiovascular-focused subsidiary Akcea Therapeutics, Inc. just as the affiliate's pipeline matures into late-stage development. Ionis announced on 31 August that it will buy the roughly 24% of Akcea it doesn't already own for $18.15 per share, or approximately $500m.

"We believe becoming one company – with one vision and one set of strategic priorities, led by one team – will deliver significant strategic value, enhancing the future success of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

More from Therapy Areas

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.